Jiangsu Hengrui Medicine
600276.SS
#463
Rank
C$60.97 B
Marketcap
$9.56
Share price
-1.68%
Change (1 day)
14.35%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2024 (TTM): C$1.37 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are C$3.88 Billion. , an increase over its 2023 earnings that were of C$0.91 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2024

Annual earnings

Year Earnings Change
2024 C$1.37 B50.69%
2023 C$0.91 B11.4%
2022 C$0.82 B-13.65%
2021 C$0.95 B-34.21%
2020 C$1.44 B15.95%
2019 C$1.24 B33.03%
2018 C$0.93 B20.89%
2017 C$0.77 B23.89%
2016 C$0.62 B11.21%
2015 C$0.56 B39.5%
2014 C$0.40 B20.61%
2013 C$0.33 B11.46%
2012 C$0.29 B29.7%
2011 C$0.23 B31.16%
2010 C$0.17 B27.92%
2009 C$0.13 B5.8%
2008 C$0.13 B79.95%
2007 C$72.36 M32.89%
2006 C$54.45 M38.19%
2005 C$39.41 M21.56%
2004 C$32.42 M13.95%
2003 C$28.45 M38.06%
2002 C$20.6 M